Can LSD and psilocybin provide relief to people suffering from difficult-to-treat conditions such as depression and anxiety? Robin Carhart-Harris is a neuroscientist and head of the Imperial Centre for Psychedelic Research, which builds on over a decade of pioneering work psychedelic research, including a clinical trial that has kick-started global efforts to develop psilocybin therapy into a licensed treatment for depression.
Rhonda Patrick explains what NAD+, why it is so important for aging and why it declines with age. She discusses some of the popular NAD+ boosters like nicotinamide riboside and nicotinamide mononucleotide, what animal and human data says and some concluding thoughts.
Petter Attia MD in conversation with David Sinclair PhD about aging, longevity, NAD and more.
Rhonda Patrick explains what NAD+, why it is so important for aging and why it declines with age. She discusses some of the popular NAD+ boosters like nicotinamide riboside and nicotinamide mononucleotide, what animal and human data says and some concluding thoughts.
Dr. Jennifer Vande Voort, a Mayo Clinic psychiatrist, discusses esketamine nasal spray — a fast-acting treatment for depression that recently was approved by the Food and Drug Administration.
Like many other drugs, ketamine has multiple effects rendering it suitable for various indications including anesthesia, sedation, acute and chronic pain relief and treatment of therapy-resistant depression.